Stryker (NYSE:SYK) Price Target Lowered to $418.00 at Needham & Company LLC

Key Points

• Needham & Company cut its price target on Stryker from $454 to $418 while retaining a "buy" rating, aligning with a MarketBeat consensus average target of about $418.26.
• Stryker missed Q1 estimates with EPS of $2.60 (vs. ~$2.98) and revenue of $6.02B (vs. ~$6.34B), but management kept FY‑2026 guidance (adjusted EPS $14.90–$15.10; organic sales growth 8%–9.5%) and said operations have largely recovered from a cyber incident.
• Director Ronda E. Stryker sold 250,000 shares for roughly $90.7M (avg. $362.92), reducing her stake and signaling notable insider selling activity.

Stryker (NYSE:SYK - Get Free Report) had its price target cut by equities researchers at Needham & Company LLC from $454.00 to $418.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the medical technology company's stock. Needham & Company LLC's price target would suggest a potential upside of 32.85% from the company's previous close.

A number of other brokerages also recently issued reports on SYK. Robert W. Baird set a $437.00 price target on Stryker in a report on Friday, January 30th. TD Cowen downgraded Stryker from a "buy" rating to a "hold" rating and set a $387.00 target price on the stock. in a research note on Monday, January 26th. UBS Group dropped their price target on Stryker from $400.00 to $380.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 17th. Barclays reiterated an "overweight" rating and set a $469.00 price target on shares of Stryker in a research note on Monday, February 2nd. Finally, BTIG Research reissued a "buy" rating and issued a $397.00 price objective on shares of Stryker in a report on Tuesday, April 14th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Stryker has a consensus rating of "Moderate Buy" and an average price target of $418.26.

Stryker Price Performance

NYSE:SYK opened at $314.64 on Friday. The firm has a market capitalization of $120.50 billion, a price-to-earnings ratio of 37.46, a PEG ratio of 1.84 and a beta of 0.92. Stryker has a 1 year low of $311.31 and a 1 year high of $404.87. The business has a 50 day simple moving average of $345.67 and a 200-day simple moving average of $356.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the business posted $2.84 earnings per share. Stryker's revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts forecast that Stryker will post 14.91 EPS for the current year.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the company's stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Godfrey Financial Associates Inc. purchased a new position in Stryker in the fourth quarter worth approximately $26,000. Sankala Group LLC purchased a new position in Stryker in the fourth quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the third quarter worth approximately $27,000. Atlas Capital Advisors Inc. purchased a new position in Stryker in the fourth quarter worth approximately $27,000. Finally, DJE Kapital AG purchased a new position in Stryker in the fourth quarter worth approximately $28,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Management kept FY‑2026 guidance intact — organic sales growth of 8%–9.5% and adjusted EPS of $14.90–$15.10, signaling confidence in medium‑term demand and execution. Stryker maintains 2026 outlook
• Positive Sentiment: Cash flow and GAAP net income showed strength (operating cash from ops surged year‑over‑year; reported profit rose to $745M), providing balance‑sheet flexibility. Q1 results: cash flow & net income up
• Positive Sentiment: Company says it has largely recovered operationally from the cyber incident, which management says disrupted the quarter but is being contained. That supports the decision to keep guidance. Stryker reports first quarter 2026 operating results
• Neutral Sentiment: Full Q1 press conference transcript and management commentary are available for details on recovery timing, regional trends and product‑line performance — useful for assessing forward visibility. Q1 2026 press conference transcript
• Negative Sentiment: Q1 adjusted EPS of $2.60 missed the consensus (~$2.98) and revenue of $6.02B fell short of estimates (~$6.34B), a headline miss that pressured the stock. Q1 earnings snapshot / consensus miss
• Negative Sentiment: Management cited softer demand for implants and complex‑procedure devices (orthopaedics, spine) and adjusted operating margin contraction (~180 bps), suggesting near‑term revenue headwinds even as recovery from the cyber event continues. Reuters: misses estimates on muted demand

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.